Program
brimonidine
Also written as “Brimonidine”, “Brimonidine Tartrate” and “CD07805/47 Gel”.
Its studies are mostly in Glaucoma · Rosacea · Glaucoma, Open-Angle · Conjunctivitis, Allergic · Hyperemia, led by 10 companies.
Drug pageBrimonidine: every studyMany companies study it; this page follows only the 52 they lead. All 104 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 220 open or running | phase 4since Apr 6, 2007 | Sep 12, 2005 | none ahead |
| Galderma Groupits history only | 100 open or running | phase 4since Sep 23, 2014 | Jun 12, 2008 | none ahead |
| Bausch Health Companiesits history only | 70 open or running | phase 3since Oct 8, 2013 | Oct 8, 2013 | none ahead |
| Eye Therapiesits history only | 30 open or running | phase 2since Jan 10, 2011 | Jan 10, 2011 | none ahead |
| Ocugenits history only | 30 open or running | phase 3since Jul 9, 2018 | Oct 10, 2017 | none ahead |
| Alconits history only | 20 open or running | phase 4since Dec 1, 2008 | May 28, 2003 | none ahead |
| Tarian Pharmaits history only | 22 open or running | phase 2since Jan 23, 2025 | Jan 23, 2025 | none ahead |
| Biogenits history only | 10 open or running | phase 4since Oct 1, 2015 | Oct 1, 2015 | none ahead |
| Innovative Medicalits history only | 10 open or running | phase 4since Jun 30, 2006 | Jun 30, 2006 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Oct 31, 2014 | Oct 31, 2014 | none ahead |
Also a collaborator on its studies: ORA and Eurotrials Brasil Consultores Cientificos Ltda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 37 studies since May 28, 2003.
- Mar 12, 2014Phase 2 study in Geographic AtrophyAbbVie · NCT02087085 · 310 enrolled · United States, Australia, France and more
- Sep 23, 2014Phase 4 study in RosaceaGalderma Group · NCT02249065 · 205 enrolled · United States
- Oct 31, 2014Teva Pharmaceutical Industries’ first study: phase 3 study in RosaceaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT02289352 · 462 enrolled · United States
- Oct 1, 2015Biogen’s first study: phase 4 study in Multiple Sclerosis, Relapsing-RemittingNew to BiogenBiogen · NCT02568111
- Nov 24, 2015Phase 4 study in RosaceaGalderma Group · NCT02616250 · 190 enrolled · United States, Canada
- Jul 19, 2016Phase 4 study in Chronic Persistent Vascular Facial ErythemaGalderma Group · NCT02856919 · 101 enrolled · Brazil
- Oct 10, 2017Ocugen’s first study: phase 2 study in Dry Eye SyndromesNew to OcugenOcugen · NCT03418727 · 84 enrolled · United States
- Jul 9, 2018Phase 3 study in Graft vs Host DiseaseOcugen · NCT03591874 · 59 enrolled · United States
- Dec 20, 2018Phase 3 study in Dry Eye SyndromesOcugen · NCT03785340 · 252 enrolled · United States
- Apr 29, 2022Phase 3 study in Ocular RednessBausch Health Companies · NCT05360784 · 380 enrolled · United States
- Oct 6, 20222 phase 3 studiesBausch Health Companies · NCT05591755, NCT05579730
- Mar 21, 2023Phase 3 study in Conjunctivitis, AllergicBausch Health Companies · NCT05815758 · 512 enrolled · United States
- Jan 23, 2025Tarian Pharma’s first study: phase 2 study in EGFR Inhibitor-associated RashNew to Tarian PharmaTarian Pharma · NCT06818058 · 60 planned · France
- Jul 3, 2025Phase 2 study in Chemotherapy Induced Peripheral NeuropathyTarian Pharma · NCT07082764 · 30 planned · France
TargetBeta
“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexmedetomidinerule | Pfizer | phase 4 | 46 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| tizanidinerule | Teva Pharmaceutical Industries | phase 4 | 11 |
| Clonidinerule | pharmafina | phase 4 | 5 |
| lofexidinerule | uswm-llc-dba-us-worldmeds | phase 3 | 15 |
Studies
All 52 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07082764Chemotherapy Induced Peripheral Neuropathy · France | 2 | Not yet recruiting | Tarian Pharma | Sep 30, 2026 | 30 |
| NCT06818058EGFR Inhibitor-associated Rash · France | 2 | Recruiting | Tarian Pharma | Sep 1, 2026 | 60 |
| NCT05815758Conjunctivitis, Allergic · United States | 3 | Completed | Bausch Health Companies | Sep 18, 2023 | 512 |
| NCT05591755Seasonal Allergic Conjunctivitis · United States | 3 | Completed | Bausch Health Companies | Aug 9, 2023 | 229 |
| NCT05579730Conjunctivitis, Allergic · United States | 3 | Completed | Bausch Health Companies | Jul 22, 2023 | 188 |
| NCT05360784Ocular Redness · United States | 3 | Completed | Bausch Health Companies | Nov 23, 2022 | 380 |
| NCT03785340Dry Eye Syndromes · United States | 3 | Completed | Ocugen | Feb 25, 2019 | 252 |
| NCT03591874Graft vs Host Disease · United States | 3 | Terminated | Ocugen | Apr 30, 2020 | 59 |
| NCT03418727Dry Eye Syndromes · United States | 2 | Completed | Ocugen | Mar 29, 2018 | 84 |
| NCT02856919Chronic Persistent Vascular Facial Erythema · Brazil | 4 | Completed | Galderma Group | Feb 8, 2017 | 101 |
| NCT02616250Rosacea · United States, Canada | 4 | Completed | Galderma Group | Sep 2016 | 190 |
| NCT02568111Multiple Sclerosis, Relapsing-Remitting | 4 | Withdrawn | Biogen | Aug 2016 | 0 |
| NCT02289352Rosacea · United States | 3 | Completed | Teva Pharmaceutical Industries | Dec 2014 | 462 |
| NCT02249065Rosacea · United States | 4 | Completed | Galderma Group | Aug 2015 | 205 |
| NCT02087085Geographic Atrophy · United States, Australia, France and more | 2 | Terminated | AbbVie | Mar 30, 2018 | 310 |
| NCT02039765Hyperemia · United States | 1 | Completed | Bausch Health Companies | Mar 2014 | 12 |
| NCT02003534Glaucoma, Open-Angle · China | 4 | Completed | AbbVie | Feb 2013 | 376 |
| NCT01959243Hyperemia · United States | 3 | Completed | Bausch Health Companies | Apr 23, 2014 | 507 |
| NCT01959230Hyperemia · United States | 3 | Completed | Bausch Health Companies | Dec 20, 2013 | 60 |
| NCT01882712Erythema | 3 | Withdrawn | Galderma Group | Sep 2015 | 0 |
| NCT01863953Glaucoma · United States | 2 | Completed | AbbVie | Dec 2013 | 112 |
| NCT01687426Glaucoma · United States | 1 | Completed | Eye Therapies | Dec 2012 | 15 |
| NCT01675609Ocular Redness · United States | 2 | Completed | Eye Therapies | Oct 2012 | 57 |
| NCT01525173Glaucoma · United States | 4 | Completed | AbbVie | Oct 2012 | 137 |
| NCT01355471Rosacea · United States, Canada | 3 | Completed | Galderma Group | Nov 2011 | 293 |
| NCT01355458Rosacea · United States, Canada | 3 | Completed | Galderma Group | Sep 2011 | 260 |
| NCT01318733Rosacea · United States | 3 | Completed | Galderma Group | Jun 2012 | 449 |
| NCT01275105Conjunctivitis, Allergic · United States | 2 | Completed | Eye Therapies | Mar 2011 | 68 |
| NCT01241240Glaucoma, Open-Angle · Colombia, Mexico | 3 | Completed | AbbVie | Sep 2013 | 192 |
| NCT01229462Glaucoma · China | – | Completed | AbbVie | Sep 2011 | 238 |
| NCT01229410Vitrectomy · United States, Czech Republic | 1 | Completed | AbbVie | May 2011 | 24 |
| NCT01217606Glaucoma, Open-Angle · Brazil | 3 | Completed | AbbVie | Sep 2014 | 185 |
| NCT01216943Glaucoma · India | 3 | Completed | AbbVie | Aug 2012 | 126 |
| NCT01174030Rosacea · United States | 2 | Completed | Galderma Group | Dec 2010 | 269 |
| NCT01151904Glaucoma, Angle-Closure · Thailand | 4 | Terminated | AbbVie | Feb 2012 | 17 |
| NCT00989014Rosacea · United States | 2 | Completed | Galderma Group | Nov 2009 | 122 |
| NCT00972374Rhegmatogenous Macula-off Retinal Detachment · United States, India, Israel and more | 2 | Completed | AbbVie | Oct 2010 | 44 |
| NCT00822055Glaucoma, Open-Angle · Canada | 4 | Completed | AbbVie | Nov 2006 | 140 |
| NCT00800540Glaucoma · United States | 4 | Completed | Alcon | Jan 2012 | 35 |
| NCT00697541Erythematous Rosacea · United States | 2 | Completed | Galderma Group | Jun 2008 | 20 |
| NCT00693485Glaucoma, Open-Angle · United States, Israel | 2 | Completed | AbbVie | Jan 2011 | 70 |
| NCT00658619Macular Degeneration · United States, Australia, Germany and more | 2 | Completed | AbbVie | Jun 1, 2010 | 119 |
| NCT00652483Glaucoma · United States | 3 | Completed | AbbVie | Dec 2003 | 433 |
| NCT00651612Glaucoma · United States | 3 | Completed | AbbVie | Jan 2007 | 604 |
| NCT00661479Retinitis Pigmentosa · United States, France, Germany and more | 2 | Completed | AbbVie | Dec 2009 | 21 |
| NCT00457795Glaucoma, Open-Angle · United States | 4 | Completed | AbbVie | Feb 2009 | 15 |
| NCT00348400Glaucoma · United States | 4 | Completed | Innovative Medical | ||
| NCT00332436Ocular Hypertension · United States | 3 | Completed | AbbVie | Nov 2001 | 586 |
| NCT00332384Ocular Hypertension · United States | 3 | Completed | AbbVie | Nov 2001 | 573 |
| NCT00332345Ocular Hypertension · United States | 2 | Completed | AbbVie | Aug 1999 | 73 |
| NCT00168363Glaucoma | 3 | Completed | AbbVie | Aug 2006 | 207 |
| NCT00061529Glaucoma, Open-Angle · United States | 3 | Completed | Alcon | Jul 2004 |
How it is read
Names in the registry
- “Brimonidine”, 4 entries
- “Brimonidine Tartrate”, 4 entries
- “CD07805/47 Gel”, 4 entries
- “CD07805/47”, 3 entries
- “400 µg Brimonidine Tartrate Implant”, 3 entries
Conditions, from the studies’ own filings
- Glaucoma, 10 studies
- Rosacea, 9 studies
- Glaucoma, Open-Angle, 8 studies
- Conjunctivitis, Allergic, 4 studies
- Hyperemia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.